2 results
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Approved WMOPending
The primary objective of the current project is to develop and test a real-time accurate neuro-mechanical model-based controllers of the lower limb The hypothesis are that the synergy-driven approach would adapt to changes in speed, the enhanced…